No Data
BOCOM INTL: AI-driven new opportunities in the onshore pharmaceutical Sector, giving the Industry a "leading" rating.
With the expectation of continued rollout of favorable policies regarding fiscal and medical insurance/commercial insurance, and the overall Sector valuation still at historical lows, BOCOM INTL believes there is still significant room for recovery in the Sector.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Hong Kong stock movement | Lepu Biopharma-B (02157) rose nearly 7% in early trading after signing an exclusive licensing agreement with ArriVent for MRG007.
Lepu Biotech-B (02157) rose nearly 7% in the morning session, and as of the time of writing, it has increased by 5.07%, priced at 2.9 Hong Kong dollars, with a transaction volume of 12.4945 million Hong Kong dollars.
Hong Kong Stock Market Midday Review | Hang Seng Index rose 0.24% in the morning session, Mainland Insurance Companies climbed across the board.
Six departments issued a document to promote the entry of medium- and long-term funds into the market. Institutions stated that expectations for improvements on the asset side have significantly increased.
A BD L worth up to 1.2 billion USD! The value potential of Lepu Biopharmaceutical-B (2157.HK) is gradually being realized.
BD is a key path for Innovative Drugs companies to grow and achieve breakthroughs in their development process.
Lepu Grants ArriVent Exclusive License for Anti-Gastrointestinal Drug Outside Greater China
